治疗儿科斑块牛皮的生物药物:系统性审查和网络元分析
Abdullah Ali Aljalfan1, Muhammad Talha Maniya2, Dilshad Sachedina3
1Department of Dermatology, King Fahad University Hospital, Al Khobar, Saudi Arabia.
概括
与安慰剂相比,生物疗法显著改善了儿童牛皮的结果. 虽然个体药物表现出趋势,但对于儿童中度至重度的斑块性牛皮,没有单一的生物药物是绝对优越的.
科学领域:
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 儿童牛皮的治疗正在随着生物使用的增加而发展.
- 在儿童中,中度至重度的斑块性牛皮需要有效的治疗选择.
研究的目的:
- 系统地审查和网络分析儿科斑块牛皮的生物治疗方法.
- 为了在这个人群中比较现有生物制剂的疗效和安全性.
主要方法:
- 在主要数据库中进行了随机对照试验 (RCT) 的系统搜索.
- 进行了一种固定效应的频率网络元分析 (NMA).
- 关键结局包括PASI75,PASI90,PASI100和12-16周的CDLQI得分.
主要成果:
- 分析了7个涉及1016名患者的RCT.
- 所有生物药物显示PASI75和PASI90反应明显高于安慰剂.
- 伊克西祖马布在PASI100中领先,Secukinumab (高剂量) 在PASI90中,Ustekinumab在PASI75和CDLQI得分中领先.
结论:
- 生物药物对儿科斑块牛皮比安慰剂有效得多.
- 没有一个单一的生物制剂显示出比其他生物制剂具有统计学上显著优势.
- 需要进一步的大规模试验来确定最佳的治疗策略.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
490
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
490
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
242
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
242
Pharmacokinetics in Pediatric Patients: Drug Metabolism
192
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
192
Pharmacokinetics in Pediatric Patients: Drug Distribution
252
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
252
Pharmacokinetics in Pediatric Patients: Drug Excretion
212
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
212
Drug Products: Biologics, Biosimilars and Interchangeables
233
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
233


